


LEGEND-T2DM Evidence Dissemination Summary

Target: **alogliptin**, Comparator: **dulaglutide** Outcome: **Diabetic ketoacidosis**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	16,755	9,788	19	1.94
Merative CCAE	-	-	-	-
Merative MDCCD	563	316	<5	<15.83
Merative MDCR	-	-	-	-
Optum Clinformatics	604	354	0	0.00
Optum EHR	1,013	219	<5	<22.78
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

